

VIA FAX: (703) 872 9306

PTO/SEA/02A (08-03)

Approved for use through 07/31/2008: OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	2	of	3
-------	---	----	---

Complete if Known

Application Number	10/629,432
Filing Date	JULY 29, 2003
First Named Inventor	DENNIS P. CURRAN
Art Unit	1624
Examiner Name	MARK L. BERCH
Attorney Docket Number	96-029 CON3

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ^o
		Country Code ² Number ³ Kind Code ⁴ (if known)				
WJB AM	B5	WO 99/01456A	01-14-1999	UNIVERSITY OF PITTSBURGH		
	B6	WO 98/35940A	08-20-1998	EPONUMERIX PHARMACEUTICALS INC.		

Examiner Signature	<i>Mark L. Buer</i>	Date Considered	5/6/07
-----------------------	---------------------	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). *See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

VIA FAX: (703) 872 9306

MAR 30 2005

PTO/SB/088 (08-03)

Approved for use through 07/31/2006, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/629,432
		Filing Date	JULY 29, 2003
		First Named Inventor	DENNIS P. CURRAN
		Art Unit	1624
		Examiner Name	MARK L. BERCH
Sheet 3 of 3	Attorney Docket Number	96-029 CON3	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MB	C1	CURRAN, D.P. and LIU, H., "New 4+1 Radical Annulations - A Formal Total Synthesis of (+/-)-Camptothecin," J. Am. Chem. Soc., 114, 5863-5864 (1992). Published 7/1/92	
MB	C2	CURRAN, D.P., "The Camptothecins - A reborn Family of Antitumor Agents," J. Chin. Chem. Soc., 40, 1-6 (1993). Published 2/1993	
MB	C3	CURRAN, D.P. et al., "Recent Applications of Radical Reactions in Natural Product Synthesis," Pure Appl. Chem., 65, 1153-1159 (1993). Published 6/93	
MB	C4	CURRAN, D.P. et al., "Cascade Radical Reactions of Isonitriles: A Second-Generation Synthesis of (20S)-Camptothecin, Topotecan, Irinotecan, and GI-147211C," Angew. Chem. Int. Ed. 34, 2683-2684 (1995). Published 1/5/96	
MB	C5	CURRAN, D.P., Liu, H.; Josien, H; Ko, S.B., "Tandem Radical Reactions of Isonitriles with 2-pyridonyl and other aryl radicals: Scope and Limitations, and a First Generation Synthesis of (+/-)-Camptothecin," Tetrahedron, 52, 11385-11404 (1996). Published 8/96	
MB	C6	JOSIEN, H. and CURRAN, D.P., "Synthesis of (S)-mappicine and Mappicine Ketone Via Radical Cascade Reaction of Isonitriles," Tetrahedron, 53, 8881-8886 (1997). Published 6/30/97	
MB	C7	LIU, H. et al., "Selective N-Functionalization of 6-Substituted-2-Pyridones," Tetrahedron Letters, 36:49, 8917-8920 (1995).	
MB	C8	JOSIEN H. et. al. "7-Silylcampthothecins (Silatecans): A New Family of Campthothecin Antitumor Agents", Bioorganic & medical Chemistry Letters, Oxford, GB, vol. 7, No. 24, Dec-16-1997, pages 3189-3194.	
MB	C9	WALL M.E. et. al. "campthothecin and Taxol: From Discovery to Clinic", Journal of Ethnopharmacology, vol. 51, 1996, pages 239-254.	
MB	C10	GOLDWASSER F. et. al. "potentiation of Cisplatin Cytotoxicity by 9-Aminocampthothecin", Clinical Cancer Research, vol. 2, april 1996, pages 687-693.	

Examiner Signature	<i>Mark L. Berch</i>	Date Considered	5/6/05
--------------------	----------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.